Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Acquired by Evergreen Capital Management LLC

Evergreen Capital Management LLC lifted its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 5.4% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 3,143 shares of the company’s stock after acquiring an additional 160 shares during the quarter. Evergreen Capital Management LLC’s holdings in Prestige Consumer Healthcare were worth $216,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Norges Bank acquired a new position in Prestige Consumer Healthcare during the fourth quarter worth $27,739,000. UBS Group AG lifted its stake in Prestige Consumer Healthcare by 377.6% during the 4th quarter. UBS Group AG now owns 131,382 shares of the company’s stock worth $8,043,000 after acquiring an additional 103,872 shares in the last quarter. Franklin Resources Inc. boosted its holdings in Prestige Consumer Healthcare by 9.6% during the 4th quarter. Franklin Resources Inc. now owns 20,057 shares of the company’s stock valued at $1,228,000 after acquiring an additional 1,764 shares during the period. Hsbc Holdings PLC grew its position in Prestige Consumer Healthcare by 8.9% in the 4th quarter. Hsbc Holdings PLC now owns 24,050 shares of the company’s stock valued at $1,469,000 after acquiring an additional 1,975 shares in the last quarter. Finally, Parallel Advisors LLC increased its stake in Prestige Consumer Healthcare by 42.5% during the fourth quarter. Parallel Advisors LLC now owns 714 shares of the company’s stock worth $44,000 after purchasing an additional 213 shares during the period. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Stock Down 0.0 %

Shares of Prestige Consumer Healthcare stock opened at $71.32 on Friday. The company has a quick ratio of 1.90, a current ratio of 3.23 and a debt-to-equity ratio of 0.65. Prestige Consumer Healthcare Inc. has a 52-week low of $56.34 and a 52-week high of $75.80. The company has a market capitalization of $3.53 billion, a P/E ratio of 17.10, a P/E/G ratio of 2.01 and a beta of 0.48. The company has a 50 day moving average of $71.21 and a 200 day moving average of $69.63.

Prestige Consumer Healthcare (NYSE:PBH) last issued its earnings results on Thursday, August 8th. The company reported $0.90 EPS for the quarter, topping analysts’ consensus estimates of $0.86 by $0.04. Prestige Consumer Healthcare had a net margin of 18.43% and a return on equity of 12.55%. The firm had revenue of $267.10 million during the quarter, compared to the consensus estimate of $260.54 million. During the same quarter in the previous year, the firm posted $1.06 earnings per share. The company’s revenue was down 4.4% compared to the same quarter last year. As a group, research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.43 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

PBH has been the subject of several recent research reports. Jefferies Financial Group reissued a “hold” rating and issued a $76.00 price objective (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. DA Davidson raised their price target on shares of Prestige Consumer Healthcare from $93.00 to $95.00 and gave the company a “buy” rating in a research report on Wednesday, August 28th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $94.20.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.